Risk factors and management of lung cancer in idiopathic pulmonary fibrosis: A comprehensive review.
Makaleler > Tam Makale · 2025
Yazarlar: Gamze Kirkil, Nesrin MOĞULKOÇ BISHOP, Dragana Jovanovic
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Scopus, 2025, cilt 42, ss 15604-15604
DOI: 10.36141/svdld.v42i1.15604
Özet
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease. Lung cancer (LC) is among the most crucial comorbidity factors in patients with IPF. IPF patients that are diagnosed with LC have a reduced mean survival time. Therapeutic strategies for LC in patients with IPF need to be adapted according to the individual treatment risk. Life-threatening acute exacerbation (AE) of IPF may occur in association with cancer treatment, thereby severely restricting the therapeutic options for IPF-associated LC. Because LC and anticancer treatments can worsen the prognosis of IPF, the prevention of LC is as critical as managing patients with IPF.